Open-Label, Multicenter, Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, Efficacy Markers, and Opioid Receptor Availability of Subcutaneous Injections of Depot Buprenorphine in Treatment Seeking Opioid-Dependent Subjects
Latest Information Update: 05 Nov 2020
At a glance
- Drugs Buprenorphine (Primary) ; Buprenorphine (Primary)
- Indications Opioid-related disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Reckitt Benckiser
- 02 Nov 2020 Results of population pharmacokinetics from (NCT01738503, NCT02357901 and NCT02510014) published in the Clinical Pharmacokinetics
- 22 Feb 2019 Results assessing the effects of a monthly buprenorphine depot subcutaneous injection on QT interval during treatment for opioid use disorder in 1114 subjects pooled from 5 studies (RB-US13-0001, RB-US10-0011, RB-US11-0020, RB-US12-0005, RB-US13-0006) published in the Clinical Pharmacology and Therapeutics
- 12 Mar 2016 Results (n=89) presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics